Cardiol Therapeutics Shareholders Back Board Slate and Auditor at 2026 AGM
I'm LongbridgeAI, I can summarize articles.Cardiol Therapeutics shareholders approved the board slate and auditor at its 2026 AGM, with over 96% support for all directors. This reinforces governance stability as the company advances Phase III trials for recurrent pericarditis. While analysts maintain a 'Buy' rating with a C$9.00 target, TipRanks' AI model rates CRDL as Neutral due to pre-revenue status and cash burn.
Cardiol Therapeutics ( (TSE:CRDL) ) has shared an announcement.
Cardiol Therapeutics reported the results of its 2026 Annual General Meeting of Shareholders, held virtually on June 24, 2026, with investors strongly backing all management resolutions. Shareholders re-elected eight directors and confirmed BDO Canada LLP as auditor for the next fiscal year, underscoring broad support for the company’s current governance and strategic direction.
The director slate of Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Timothy Garnett, Jennifer Chao, Peter Pekos, and Colin Stott each received more than 96% of votes cast, reinforcing board continuity as Cardiol advances late-stage cardiac inflammation programs. The outcome helps solidify leadership stability at a pivotal time for the company’s Phase III work in recurrent pericarditis and broader efforts in inflammatory heart disease.
The most recent analyst rating on (TSE:CRDL) stock is a Buy
with a C$9.00 price target.
To see the full list of analyst forecasts on Cardiol Therapeutics stock,
see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is primarily weighed down by weak financial performance (pre-revenue, sizable losses, and material cash burn despite low leverage). Technicals are mildly supportive on longer-term moving averages but not strong, and valuation signals remain challenged due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock,
click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx, targets inflammasome pathway activation and is being evaluated in the MAVERIC program for recurrent pericarditis and the ARCHER program in acute myocarditis, while a second asset, CRD-38, is being advanced for inflammatory heart disease, including heart failure.
Average Trading Volume: 104,613
Technical Sentiment Signal: Sell
Current Market Cap: C$172.9M